Baird analyst Colleen Kusy lowered the firm’s price target on Oric Pharmaceuticals to $25 from $27 and keeps an Outperform rating on the shares. The firm noted they reported Q423 results and notably, timelines for its lead two programs remain on track and Baird remains particularly bullish on the ORIC-944 opportunity, and so reiterate their rating and adjust our price target to reflect the recent capital raise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ORIC:
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
- Oric Pharmaceuticals CEO Chacko sells 40,000 common shares
- ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Oric Pharmaceuticals price target raised to $20 from $12 at Wedbush